NSE - Delayed Quote INR

Sun Pharma Advanced Research Company Limited (SPARC.NS)

Compare
208.06 -1.23 (-0.59%)
At close: 3:30 PM GMT+5:30
Currency in INR All numbers in thousands
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
3/31/2020
Total Revenue
684,053.00
755,453.00
2,387,801.00
1,372,489.00
2,529,571.00
--
Cost of Revenue
1,167,059.00
1,357,859.00
1,767,365.00
1,310,748.00
2,066,670.00
--
Gross Profit
-483,006.00
-602,406.00
620,436.00
61,741.00
462,901.00
--
Operating Expense
3,544,235.00
3,512,635.00
2,856,879.00
2,022,469.00
1,921,911.00
--
Operating Income
-4,027,241.00
-4,115,041.00
-2,236,443.00
-1,960,728.00
-1,459,010.00
--
Net Non Operating Interest Income Expense
234,813.00
237,813.00
-393.00
-119,183.00
-97,532.00
--
Pretax Income
-3,869,819.00
-3,868,319.00
-2,225,835.00
-2,033,954.00
-1,511,388.00
--
Tax Provision
7,820.00
3,820.00
--
--
--
--
Net Income Common Stockholders
-3,877,639.00
-3,872,139.00
-2,225,835.00
-2,033,954.00
-1,511,388.00
--
Diluted NI Available to Com Stockholders
-3,877,639.00
-3,872,139.00
-2,225,835.00
-2,033,954.00
-1,511,388.00
--
Basic EPS
-11.95
-11.93
-7.82
-7.73
-5.77
--
Diluted EPS
-11.95
-11.93
-7.82
-7.73
-5.77
--
Basic Average Shares
324,438.28
324,521.59
284,695.96
263,144.17
262,047.51
--
Diluted Average Shares
324,438.28
324,521.59
284,695.96
263,144.17
262,047.51
--
Rent Expense Supplemental
--
2,508.00
--
--
--
--
Total Expenses
4,711,294.00
4,870,494.00
4,624,244.00
3,333,217.00
3,988,581.00
--
Net Income from Continuing & Discontinued Operation
-3,877,639.00
-3,872,139.00
-2,225,835.00
-2,033,954.00
-1,511,388.00
--
Normalized Income
-3,903,975.80
-3,898,475.80
-2,257,358.00
-2,087,525.00
-1,521,691.00
--
Interest Income
--
254,759.00
75,954.00
14,104.00
8,971.00
--
Interest Expense
14,946.00
11,946.00
76,347.00
133,287.00
106,503.00
--
Net Interest Income
234,813.00
237,813.00
-393.00
-119,183.00
-97,532.00
--
EBIT
-3,854,873.00
-3,856,373.00
-2,149,488.00
-1,900,667.00
-1,404,885.00
--
EBITDA
-3,729,368.00
-3,731,268.00
-2,031,780.00
-1,799,048.00
-1,295,652.00
--
Reconciled Cost of Revenue
1,167,059.00
1,357,859.00
1,767,365.00
1,310,748.00
2,066,670.00
--
Reconciled Depreciation
125,505.00
125,105.00
117,708.00
101,619.00
109,233.00
--
Net Income from Continuing Operation Net Minority Interest
-3,877,639.00
-3,872,139.00
-2,225,835.00
-2,033,954.00
-1,511,388.00
--
Total Unusual Items Excluding Goodwill
37,624.00
37,624.00
31,523.00
53,571.00
10,303.00
--
Total Unusual Items
37,624.00
37,624.00
31,523.00
53,571.00
10,303.00
--
Normalized EBITDA
-3,766,992.00
-3,768,892.00
-2,063,303.00
-1,852,619.00
-1,305,955.00
--
Tax Rate for Calcs
0.00
0.00
--
--
--
--
Tax Effect of Unusual Items
11,287.20
11,287.20
--
--
--
--
3/31/2020 - 1/14/2003

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers